Source: Gene Online, June 2025
A recent study presented at the ASCO 2025 conference highlights findings on the safety and efficacy of a combination therapy involving encorafenib and binimetinib for patients with resected stage II melanoma. The research focuses specifically on individuals with high-risk BRAF-mutated melanoma, a genetic subtype associated with increased disease progression.
The study examined the impact of this targeted therapy in improving outcomes for patients following surgical removal of their tumors. Researchers evaluated both safety profiles and therapeutic effectiveness, noting promising results in reducing recurrence rates among participants.